Instil Bio Inc. (TIL)
Healthcare
Biotechnology
7.10 $
-0.3%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Instil Bio Inc. (TIL)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 53.4% of the shares are freely tradable; institutional investors hold 62.2%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
62.2%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
6.6%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
53.4%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
5.8%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
7Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BML Capital Management LLC | 9.52 | 645,600 | +0.0 | 03/31/2026 |
| Cpmg Inc | 6.06 | 410,922 | +0.0 | 03/31/2026 |
| Kalehua Capital Management LLC | 4.76 | 322,879 | +0.0 | 03/31/2026 |
| Vivo Capital, LLC | 4.32 | 292,743 | +0.0 | 03/31/2026 |
| Vanguard Group Inc | 2.82 | 191,060 | +13.9 | 12/31/2025 |
| Vanguard Capital Management, LLC | 2.57 | 174,583 | +0.0 | 03/31/2026 |
| Millennium Management LLC | 1.96 | 132,946 | -45.2 | 03/31/2026 |
| Renaissance Technologies Corp | 0.87 | 59,100 | -12.8 | 03/31/2026 |
| BlackRock Inc | 0.77 | 52,018 | +1.6 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 1.75 | 118,992 | +0.0 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.